| | 73963-72-1 Basic information More.. |
| Product Name: | Cilostazol | | Synonyms: | 6-[4-(1-CYCLOHEXYL-1H-TETRAZOL-5-YL)BUTOXY]-3,4-DIHYDRO-2(1H)-QUINOLINONE;6-[4-(1-cyclohexyl-1h-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1h)-quinolinone additional name: 6-[4-(1-cyclohexyl-5-tetrazolyl)butoxy]-1,2,3,4- tetrahydro-2-oxoquinolinone;OPC-13013, Pletal, 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone;6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one;CILOSTAZOL JP;6-[4-(1-CYCLOHEXYL-1H-TETRAZOL-5-YL)BUTOXY]-3,4-DIHYDRO-2(1H)-QUINOLINONE(CILOSTAZOL);OPC 13013, OPC 21, Pletaal, 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone;6-[4-(1-Cyclohexyl-1H-tetrazol-5-y1)butoxy]-3，4-dihydrcr2(1H)-quinolinone | | CAS: | 73963-72-1 | | MF: | C20H27N5O2 | | MW: | 369.46 | | EINECS: | 689-122-9 | | Mol File: | 73963-72-1.mol |  |
Use
Cilostazol is a platelet aggregation inhibitor with cerebral vasodilating activity, indicated
for use in stroke and myocardial infarction. In patients with cerebral thrombosis, transient
ischemia and cerebral arteriosclerosis, cilostazol significantly inhibits ADP-, collagenand
epinephrine-induced platelet aggregation. Side effects include headache and
tachycardia.
- Cilostazol
-
- US $0.00 / KG
- 2024-09-18
- CAS:73963-72-1
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 800kg/month
- Cilostazol
-
- US $0.00-0.00 / KG
- 2024-08-26
- CAS:73963-72-1
- Min. Order: 1KG
- Purity: USP, BP
- Supply Ability: 5,000KG
- Cilostazol
-
- US $0.00 / KG
- 2024-03-16
- CAS:73963-72-1
- Min. Order: 100g
- Purity: 98%+
- Supply Ability: 100kg
|
|
73963-72-1
Recommend Suppliers |
|